Skip to main content
. 2021 Oct 31;61(3):387–400. doi: 10.1007/s40262-021-01071-5

Fig. 2.

Fig. 2

Boxplot of inebilizumab clearance (mL/d) by ADA status. ADA antidrug antibody, ADA NEG ADA-negative subject with titer <50, ADA POS ADA-positive subject with titer ≥50, N sample size